Innate Pharma S.A. (IPHA)
Market Cap | 197.25M |
Revenue (ttm) | 68.49M |
Net Income (ttm) | -8.41M |
Shares Out | 80.84M |
EPS (ttm) | -0.10 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 9,449 |
Open | 2.300 |
Previous Close | 2.400 |
Day's Range | 2.250 - 2.500 |
52-Week Range | 1.810 - 3.570 |
Beta | 0.67 |
Analysts | Strong Buy |
Price Target | 11.50 (+371.31%) |
Earnings Date | Mar 21, 2024 |
About IPHA
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head an... [Read more]
Financial Performance
In 2023, Innate Pharma's revenue was 61.64 million, an increase of 6.88% compared to the previous year's 57.67 million. Losses were -7.57 million, -86.97% less than in 2022.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to one analyst, the rating for IPHA stock is "Strong Buy" and the 12-month stock price forecast is $11.5.
News
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to hold its Annual General Meeting of shareholders on May 23, 2024.
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was dosed in the P...
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that first preclinical data for i...
Innate Pharma Announces Its Participation in Upcoming Investor Conference
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in upcoming Investor Conference.
Innate Pharma Files Its 2023 Universal Registration Document (Document d'enregistrement Universel) and 2023 Annual Report on Form 20-F
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma files its 2023 Universal Registration Document (Document d'enregistrement Universel) and 2023 Annual Report on Form 20-F.
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma reports Full Year 2023 financial results and business update.
Innate Pharma Announces Its Participation to Upcoming Investor Conference
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are sc...
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference ...
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's Lymphoma
MARSEILLE, France--(BUSINESS WIRE)--First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's Lymphoma.
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to present Nectin-4 Antibody Drug Conjugate IPH45 preclinical data at AACR 2024.
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Admin...
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it has strengthened the Company's le...
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced today that Sanofi has exercised its option to lice...
Innate Pharma Announces Leadership Change
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Mondher Mahjoubi has resigned from his position as Chief Execu...
Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that the updated efficacy and safety results from an open-...
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced positive final results from the Phase 2 TELLOMAK s...
Innate Pharma to Host Virtual KOL Event on Lacutamab
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host a virtual KOL (Key Opinion Leade...
Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its revenues and cash position for the first nine months o...
Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the Company will hold a conference call on Tuesday, N...
Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces new clinical data for lacutamab and SAR443579/IPH6101 at ASH 2023.
Innate Pharma Announces Its Participation to Upcoming Investor Conferences
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled t...
Innate Pharma 2024 Financial Calendar
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Innate Pharma 2024 Financial calendar.
Innate Pharma Announces Abstracts Selected for ESMO Congress 2023
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the following presentations will be presented at the ...
Innate Pharma Provides Update on Lacutamab Clinical Program
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has placed a parti...
Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced an encore presentation of interim efficacy results...